Lipids Are the Preferred Substrate of the Protist Naegleria gruberi, Relative of a Human Brain Pathogen

Naegleria gruberi is a free-living non-pathogenic amoeboflagellate and relative of Naegleria fowleri, a deadly pathogen causing primary amoebic meningoencephalitis (PAM). A genomic analysis of N. gruberi exists, but physiological evidence for its core energy metabolism or in vivo growth substrates is lacking. Here, we show that N. gruberi trophozoites need oxygen for normal functioning and growth and that they shun both glucose and amino acids as growth substrates. Trophozoite growth depends mainly upon lipid oxidation via a mitochondrial branched respiratory chain, both ends of which require oxygen as final electron acceptor. Growing N. gruberi trophozoites thus have a strictly aerobic energy metabolism with a marked substrate preference for the oxidation of fatty acids. Analyses of N. fowleri genome data and comparison with those of N. gruberi indicate that N. fowleri has the same type of metabolism. Specialization to oxygen-dependent lipid breakdown represents an additional metabolic strategy in protists. Bexkens et al. show that N. gruberi amoebae live preferably on lipids, for which they need oxygen, a lifestyle largely unknown among protists. This challenges existing views about its energy metabolism, with implications for treatment of its pathogenic relative, N. fowleri, the brain-eating agent of primary amoebic me

Naegleria gruberi metabolism

The completion of the genome project for Naegleria gruberi provides a unique insight into the metabolic capacities of an organism, for which there is an almost complete lack of experimental data. The metabolism of Naegleria seems to be extremely versatile, as can be expected for a free-living amoeboflagellate, but although considered to be fully aerobic, its genome also predicts important anaerobic traits. Other predictions are that carbohydrates are oxidised to carbon dioxide and water when oxygen is not limiting and that in the absence of oxygen the end-products will be succinate, acetate and minor quantities of ethanol and D-lactate. The hybrid mitochondrion/hydrogenosome has both cytochromes and an [Fe] hydrogenase, but seems to lack pyruvate-ferredoxin oxidoreductase. Genomic information also provides the possibility to identify drugs with a possible mode of action in the fatal primary amoebic meningoencephalitis caused by the closely related opportunistic pathogen Naegleria fowleri</p

On the mathematical modelling of metabolic pathways and its use in the identification of the most suitable drug target.

Parasitic diseases are a present and worsening threat to human health and welfare around the globe. Yet current products and tools for the treatment of most parasitic diseases are predominantly limited in scope, effect and availability. Drug resistance is spreading rapidly, the development of new drugs is not keeping pace with need, and many potential vaccines have not been meeting expectations. This report details the proceedings of a meeting on "Drugs against parasitic diseases", held in Montpellier, France (24-26 1999). The goal of the meeting was the production of a basic framework to better coordinate and guide research and development of antiparasitic drugs. The meeting addressed various questions concerning drug discovery and development, with particular attention being paid to novel strategies and new technologies. There was a special focus on the promise and pitfalls of parasite genomics. The papers presented at the meeting (and published in this report) cover a selection of top priorities that would benefit from immediate R&D activities. They also attempt to provide guidance that could be used to accelerate the general development of antiparasitic drugs